Merck's cladribine gets negative CHMP opinion
This article was originally published in Scrip
Executive Summary
Merck KGaA has reaffirmed its commitment to developing cladribine to treat relapsing-remitting multiple sclerosis (RRMS) in the wake of getting knocked by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).The CHMP concluded, based on current data, that the benefits of cladribine tablets do not outweigh the risks.